| scholarly article | Q13442814 |
| P50 | author | Narikazu Boku | Q88572199 |
| Atsushi Ohtsu | Q115365827 | ||
| Kuniaki Shirao | Q115365988 | ||
| Ichinosuke Hyodo | Q118121981 | ||
| P2093 | author name string | Seiichiro Yamamoto | |
| Hiroshi Saito | |||
| Yasuhiro Shimada | |||
| Shigeaki Yoshida | |||
| Yoshinori Miyata | |||
| Haruhiko Fukuda | |||
| Japan Clinical Oncology Group Study (JCOG9205) | |||
| Noboru Yamamichi | |||
| Nobumasa Ikeda | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| clinical oncology | Q12322152 | ||
| fluorouracil | Q238512 | ||
| cisplatin | Q412415 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 54-59 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). | |
| P478 | volume | 21 |
| Q42271670 | A case of advanced gastric cancer achieved a pathological complete response by chemotherapy |
| Q43713510 | A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer |
| Q33413350 | A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer |
| Q56785971 | A patient with gastric cancer and liver metastases successfully treated with combination chemotherapy including S-1 |
| Q53248440 | A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma. |
| Q44616079 | A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting |
| Q53099235 | A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. |
| Q33421868 | A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer |
| Q33395721 | A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer |
| Q83900980 | A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Tria |
| Q46601885 | A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer |
| Q46564784 | A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial |
| Q99412202 | A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302) |
| Q33385867 | A phase II trial of paclitaxel, 5-fluorouracil (5-FU) and cisplatin in patients with metastatic or recurrent gastric cancer |
| Q37341735 | A pilot study of cisplatin, irinotecan, leucovorin and 5-fluorouracil (PILF) combination chemotherapy for advanced gastric cancer |
| Q57902299 | A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer |
| Q46076346 | Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1). |
| Q37491365 | Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). |
| Q47870382 | Adjuvant Chemotherapy vs Postoperative Observation Following Preoperative Chemoradiotherapy and Resection in Gastroesophageal Cancer: A Propensity Score-Matched Analysis. |
| Q39091817 | Advanced gastric adenocarcinoma: optimizing therapy options. |
| Q37141665 | Advanced gastric cancer: an update and future directions |
| Q37580903 | Advances in the pharmacological treatment of gastro-oesophageal cancer |
| Q43588388 | Alternating treatment with S-1 plus low-dose cisplatin and S-1 alone for advanced gastric cancer |
| Q36962398 | An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups |
| Q43567698 | An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study |
| Q35349177 | Anti-Gastrins Antiserum Combined with Lowered Dosage Cytotoxic Drugs to Inhibit the Growth of Human Gastric Cancer SGC7901 Cells in Nude Mice |
| Q53080933 | Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer. |
| Q36066079 | Available options in chemotherapy for advanced gastric cancer: the current developments in Japan |
| Q89475533 | C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer |
| Q36979346 | Capecitabine in advanced gastric cancer |
| Q34236005 | Capecitabine in gastric cancer |
| Q37136996 | Capecitabine in the treatment of advanced gastric cancer |
| Q34603290 | Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. |
| Q24236634 | Chemotherapy for advanced gastric cancer |
| Q24244040 | Chemotherapy for advanced gastric cancer |
| Q38604012 | Chemotherapy for advanced gastric cancer. |
| Q42282836 | Chemotherapy for advanced gastric cancer: a new milestone lies ahead. |
| Q34617795 | Chemotherapy for advanced gastric cancer: across the years for a standard of care |
| Q44602395 | Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). |
| Q37076553 | Chemotherapy for advanced gastric cancer: review of global and Japanese status. |
| Q37446941 | Chemotherapy for advanced gastric cancer: slow but further progress |
| Q36548725 | Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel |
| Q46540773 | Chemotherapy for gastric cancer in Japan |
| Q37191094 | Chemotherapy for metastatic disease: review from JCOG trials |
| Q37353930 | Chemotherapy for metastatic gastric cancer in Japan |
| Q37155553 | Chemotherapy for metastatic gastric cancer: past, present, and future |
| Q34395962 | Chemotherapy for patients with advanced gastric cancer with performance status 2 |
| Q26771424 | Chemotherapy in Elderly Patients with Gastric Cancer |
| Q36694149 | Chemotherapy in metastatic gastric cancer: population-based perceptions and practice patterns of medical oncologists |
| Q37832986 | Chemotherapy in the treatment of metastatic gastric cancer: is there a global standard? |
| Q85888202 | Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer |
| Q98288637 | Clinical Complete Response after Chemotherapy and Palliative Surgery for Unresectable Gastric Cancer |
| Q33398040 | Clinical outcomes of TS-1 chemotherapy for advanced and recurrent gastric cancer |
| Q43935037 | Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer |
| Q36625990 | Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer |
| Q36551182 | Combination chemotherapy with paclitaxel, cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma: a multicenter prospective study |
| Q33912151 | Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis |
| Q39462555 | Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patients |
| Q35753663 | Complications in advanced or recurrent gastric cancer patients with peritoneal metastasis during and after palliative systemic chemotherapy |
| Q37077239 | Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. |
| Q42217516 | Direct liver invasion from a gastric adenocarcinoma as an initial presentation of extranodal tumor spread |
| Q37141671 | Diverse eastern and Western approaches to the management of gastric cancer. |
| Q35208094 | Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts |
| Q38420500 | Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. |
| Q40347623 | Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer |
| Q40517538 | Early detection of nonperitoneal recurrence may contribute to survival benefit after curative gastrectomy for gastric cancer |
| Q47237727 | Effect of RECIST revision on classification of target lesions and overall response in advanced gastric cancer patients. |
| Q40364348 | Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma |
| Q44328704 | Efficacy and safety profile of S-1 in patients with metastatic gastric cancer in clinical practice: results from a post-marketing survey |
| Q33411751 | Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial |
| Q39695552 | Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination |
| Q46839142 | Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer |
| Q36411935 | Efficacy of paclitaxel-based doublet regimens combining with intraperitoneal chemotherapy for advanced gastric cancer with peritoneal metastasis |
| Q33903658 | Eight-year survival after advanced gastric cancer treated with S-1 followed by surgery |
| Q84107291 | First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer |
| Q39728271 | Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Cancer: a Bayesian Network Meta-Analysis. |
| Q43264239 | Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study |
| Q36503383 | Follow-up of gastric cancer: a review |
| Q37959111 | Future perspectives for the development of chemotherapy for advanced gastric cancer: Japanese and global status |
| Q89391950 | Gastric cancer |
| Q38120288 | Gastric cancer pharmacogenetics: progress or old tripe? |
| Q36450770 | Gastric cancer: an update |
| Q39183879 | Generalized high bone mineral density on bone density scanning: a case of gastric carcinoma with bone metastasis |
| Q51309951 | Giant Krukenberg tumor from a perforated gastric cancer that was successfully removed after multidisciplinary therapy: report of a case. |
| Q38813532 | Global chemotherapy development for gastric cancer |
| Q37077212 | Global perspectives on chemotherapy for patients with gastric carcinoma: a roundtable discussion. |
| Q53140602 | How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?. |
| Q38359626 | Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples |
| Q33317139 | Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer |
| Q81234955 | Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site |
| Q54703477 | Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial. |
| Q83498877 | Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment |
| Q42173252 | Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens |
| Q33400558 | Irinotecan plus mitomycin C as second-line chemotherapy for advanced gastric cancer resistant to fluoropyrimidine and Cisplatin: a retrospective study |
| Q33393276 | Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials |
| Q53379444 | Is chemotherapy in elderly patients with metastatic or recurrent gastric cancer as tolerable and effective as in younger patients? |
| Q37589204 | Is there a role for second-line chemotherapy in advanced gastric cancer? |
| Q89724644 | Japanese gastric cancer treatment guidelines 2018 (5th edition) |
| Q37079108 | Locally advanced and metastatic gastric cancer: current management and new treatment developments |
| Q80676121 | Long-term outcomes of patients with metastatic gastric cancer after initial S-1 monotherapy |
| Q33425150 | Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma |
| Q37642780 | ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer |
| Q38157342 | Management of gastric cancer in Asia: resource-stratified guidelines |
| Q34608222 | Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer |
| Q33374059 | Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial |
| Q46616879 | Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination |
| Q41135814 | Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients |
| Q33594906 | Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan |
| Q44849722 | Oral 5-FU and digestive cancers |
| Q50647977 | Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancer. |
| Q44973213 | Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases |
| Q35936039 | Palliative chemotherapy for advanced gastric cancer |
| Q37943285 | Past and present achievements, and future direction of the Gastrointestinal Oncology Study Group (GIOSG), a Division of Japan Clinical Oncology Group (JCOG). |
| Q64124471 | Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial |
| Q54547540 | Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer. |
| Q24810562 | Phase I dose-escalating study of docetaxel in combination with 5-day continuous infusion of 5-fluorouracil in patients with advanced gastric cancer |
| Q64066802 | Phase I open-label trial of intraperitoneal paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced gastric cancer and peritoneal metastases (IPGP study): study protocol |
| Q42863444 | Phase I study of Paclitaxel, Cisplatin and 5-fluorouracil combination chemotherapy for unresectable / recurrent gastric cancer |
| Q46683166 | Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer |
| Q42984481 | Phase I study of docetaxel, cisplatin and S-1 in patients with advanced gastric cancer |
| Q84523134 | Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas |
| Q36673543 | Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer |
| Q36614109 | Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer |
| Q36612612 | Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer |
| Q36615597 | Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma |
| Q36614394 | Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer |
| Q33378971 | Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin |
| Q44149643 | Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404). |
| Q36614148 | Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma |
| Q33909699 | Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer |
| Q85275232 | Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis |
| Q33361500 | Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. |
| Q46287658 | Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer |
| Q35051856 | Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. |
| Q33370303 | Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine |
| Q40505607 | Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma |
| Q37109776 | Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. |
| Q37676972 | Predictive factors improving survival after gastrectomy in gastric cancer patients with peritoneal carcinomatosis |
| Q42323722 | Preliminary trial of adjuvant surgery for advanced gastric cancer |
| Q41889228 | Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination |
| Q53622300 | Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer. |
| Q34325743 | Programmed chemotherapy for patients with metastatic unresectable gastric cancer. |
| Q39778923 | Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials |
| Q37197679 | Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis |
| Q43206575 | Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer |
| Q37235534 | Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer |
| Q46350650 | Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). |
| Q33380002 | Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction |
| Q34669648 | Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002) |
| Q37234210 | Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer |
| Q42181610 | Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials |
| Q34389753 | Recent advances in chemotherapy for advanced gastric cancer |
| Q37719335 | Recent advances in chemotherapy for advanced gastric cancer in Japan |
| Q61773324 | Recent developments in the clinical activity of topoisomerase-1 inhibitors |
| Q36376439 | Recent developments in the systemic therapy of advanced gastroesophageal malignancies |
| Q35445166 | Refining docetaxel-containing therapy for gastric cancer. |
| Q48569564 | Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm. |
| Q79291006 | Retrospective analysis of stage IV advanced gastric cancer treated with S-1 or other chemotherapy |
| Q36505106 | Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers |
| Q37052880 | Review of docetaxel in the treatment of gastric cancer |
| Q34588472 | S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial |
| Q42263964 | S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis |
| Q35070531 | S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis. |
| Q33415440 | S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials |
| Q37815444 | Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer |
| Q37992841 | Second-line chemotherapy for advanced gastric cancer in Korea |
| Q37904800 | Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials |
| Q38750633 | Second-line chemotherapy for patients with advanced gastric cancer. |
| Q41044387 | Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis |
| Q84209941 | Significance of volume-reduction surgery for far-advanced gastric cancer during treatment with novel anticancer agents |
| Q43801555 | Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgery |
| Q34395983 | Standard First-Line Chemotherapy for Metastatic Gastric Cancer in Japan Has Met the Global Standard: Evidence From Recent Phase III Trials. |
| Q89849365 | Successful Neurological Recovery with Multimodality Therapy without Surgery for Spinal Metastases from Advanced Gastric Cancer |
| Q44012763 | Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912. |
| Q46589174 | Systemic chemotherapy of TS-1 and cisplatin for gastric signet-ring cell carcinoma presenting as cardiac tamponade |
| Q37923311 | Systemic therapy for advanced gastric cancer: a clinical practice guideline |
| Q34205672 | Targeted therapies for gastric cancer: current status |
| Q26747708 | Taxanes in the Treatment of Advanced Gastric Cancer |
| Q35599748 | Tegafur/gimeracil/oteracil (S-1) approved for the treatment of advanced gastric cancer in adults when given in combination with cisplatin: a review comparing it with other fluoropyrimidine-based therapies |
| Q38941416 | The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis |
| Q30238920 | The current situation for gastric cancer in Chile |
| Q40383915 | The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma |
| Q53259376 | The efficacy of gastrectomy for large gastric cancer. |
| Q35643973 | The impact of hemoglobin level and transfusion on the outcomes of chemotherapy in gastric cancer patients. |
| Q33402388 | The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials |
| Q37959113 | The roles of surgical oncologists in the new era: minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer |
| Q36695672 | Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer |
| Q27851578 | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial |
| Q53458026 | Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy. |
| Q34661367 | Treatment options in patients with metastatic gastric cancer: current status and future perspectives |
| Q37183479 | Upper gastrointestinal tumors: current status and future perspectives |
| Q82931072 | Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer |
Search more.